We are joined by Paolo Ghia at EHA 2019 to discuss his presentation on ASCEND phase III study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL).
Questions
- What are the current treatment options for relapsed/refractory CLL and what are their limitations? (0.05)
- What is the rationale for the use of acalabrutinib in this treatment setting? (0.46)
- Could you tell us a little about the ASCEND study? (1.21)
- What further studies are planned? (1.57)
Paolo Ghia has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
